36
Participants
Start Date
June 30, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
March 31, 2012
Panobinostat (LBH589), Carboplatin and Paclitaxel
"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
Mèdecin Adjoint, ME - CePO, CHUV, Lausanne
Huniversitätsspitals Basel, Basel
Istituto Oncologico della Svizzera Italiana, Bellinzona
Collaborators (1)
Novartis
INDUSTRY
Southern Europe New Drug Organization
OTHER